Influenza virus is a highly contagious respiratory pathogen, contributing significantly to the worldwide burden of mortality and morbidity (1). They are single stranded RNA virus of the family orthomyxoviridae, characterized by specific cell surface proteins Hemagglutinin (HA) and Neuraminidase(NA) that generate specific immune response. These surface proteins undergo frequent mutations by antigenic shift and drift which may result in generation of novel viral strain, which, in turn result in seasonal epidemics of influenza with different severity.
Earlier FDA has approved the drugs, M2 ion channel inhibitors (Amantidine and Rimantidine), but they are no longer recommended owing to the high resistance against Influenza A virus (2). Existing influenza drug treatment is limited to neuraminidase inhibitors (Oseltamivir, Zanamivir), but the antiviral therapy should be started within 48 hours of the onset of symptoms for it to be effective (3). Another limitation of these drugs is the increasing number of drug resistance cases against these inhibitors which is a serious matter of concern (4). Vaccination is considered to be an alternative and …show more content…
There has long been concern about whether the vaccine offers sufficient protection in elderly individuals (11). The present study evaluates the protective efficacy of the TIV in adults >65 years old by studying the antibody response elicited in response to vaccination and the duration of protection conferred by the vaccine. The antibody response was measured by Hemagglutination Inhibition Assay (HI) and Microneutralization Assay(MN). This study further validates the usage of vaccine in elderly individuals and the duration of protection provided by
Earlier FDA has approved the drugs, M2 ion channel inhibitors (Amantidine and Rimantidine), but they are no longer recommended owing to the high resistance against Influenza A virus (2). Existing influenza drug treatment is limited to neuraminidase inhibitors (Oseltamivir, Zanamivir), but the antiviral therapy should be started within 48 hours of the onset of symptoms for it to be effective (3). Another limitation of these drugs is the increasing number of drug resistance cases against these inhibitors which is a serious matter of concern (4). Vaccination is considered to be an alternative and …show more content…
There has long been concern about whether the vaccine offers sufficient protection in elderly individuals (11). The present study evaluates the protective efficacy of the TIV in adults >65 years old by studying the antibody response elicited in response to vaccination and the duration of protection conferred by the vaccine. The antibody response was measured by Hemagglutination Inhibition Assay (HI) and Microneutralization Assay(MN). This study further validates the usage of vaccine in elderly individuals and the duration of protection provided by